Refine
Year of publication
Document Type
- Preprint (689)
- Article (589)
- Working Paper (10)
- Conference Proceeding (3)
- Part of Periodical (2)
- Part of a Book (1)
- Report (1)
Has Fulltext
- yes (1295)
Is part of the Bibliography
- no (1295)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Hepatocellular carcinoma (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- COVID-19 (3)
- Cirrhosis (3)
- Gene expression (3)
- HIV (3)
- Heavy Ions (3)
- Immunology (3)
- Inflammation (3)
- Jets and Jet Substructure (3)
- Liver diseases (3)
- cancer (3)
- child (3)
- pp collisions (3)
- Antitrust (2)
- Beauty production (2)
- Bone density (2)
- Charm physics (2)
- Consumer Welfare (2)
- Diagnostic markers (2)
- Ewing sarcoma (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- HCC (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Literaturtheorie (2)
- MLL (2)
- Mouse models (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Psychiatric disorders (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Single electrons (2)
- Sustainability (2)
- aortic stenosis (2)
- biomarker (2)
- children (2)
- habitat destruction (2)
- hematopoietic stem cell transplantation (2)
- invasive fungal disease (2)
- lung cancer (2)
- proteomics (2)
- soft tissue sarcoma (2)
- sphingolipids (2)
- web archiving (2)
- 15-PGDH (1)
- 900 GeV (1)
- ACURATE neo (1)
- AKI (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- ALL (1)
- AML (1)
- APRI (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Actin (1)
- Active middle ear implants (1)
- Acute coronary syndrome (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Amino acid analysis (1)
- Anandamide (1)
- Angiogenesis (1)
- Animal models (1)
- Anti-nuclei (1)
- Antibiotic steward-ship (1)
- Antibiotic therapy (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Apoptosis (1)
- Artificial Intelligence (1)
- Ataxia-telangiectasia (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atoms (1)
- Atrial fibrillation (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Autorschaft (1)
- BFIS (1)
- BRAF (1)
- Backscattering (1)
- Beam loss (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomarkers (1)
- Biomass monitoring (1)
- Biomonitoring (1)
- Bioprocess automation (1)
- Bipolar disorder (1)
- Blood plasma (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Breast cancer (1)
- Breast tumors (1)
- Buprestidae (1)
- C6 ceramide (1)
- CCL2 (1)
- CEP68 (1)
- COMT (1)
- COVID 19 (1)
- CRISPR/Cas (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer chemotherapy (1)
- Cancer detection and diagnosis (1)
- Cancer treatment (1)
- Canopy height model (1)
- Cardiac hypertrophy (1)
- Cardiac surgery (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell binding (1)
- Cell membranes (1)
- Cell staining (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cerambycidae (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Checkpoint inhibitor (1)
- Chronic hepatitis C (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Colorectal cancer (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- CuveWaters (1)
- C‐reactive protein (1)
- DNA sequence analysis (1)
- DST (1)
- Data sharing (1)
- Denervation (1)
- Diauxic effects (1)
- Differentiation (1)
- Digestive system procedures (1)
- Digitization (1)
- Dilated cardiomyopathy (1)
- Direct Acting Antivirals (DAA) (1)
- Drug susceptibility testing (1)
- Dual-energy computed tomography (1)
- ESBL (1)
- ESG (1)
- ETP-ALL (1)
- Early goal-directed therapy (1)
- Eicosanoids (1)
- Electroantennography (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Empirische Ästhetik (1)
- European Society for Immunodeficiencies (ESID) (1)
- Extended donor criteria (1)
- F508del homozygous (1)
- FDM (1)
- FGFR (1)
- FIB-4 (1)
- FLT3 (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Flow cytometry (1)
- Forschung (1)
- Forschungsdatenmanagement (1)
- Functional clustering (1)
- G-protein-coupled receptors (1)
- GWAS (1)
- Gastric cancer (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetics (1)
- Genome editing (1)
- German PID-NET registry (1)
- Gomphus flavipes (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Gαq/11 (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HDAC4 (1)
- HIF1α (1)
- HIPPO signalling (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Haploidentical stem cell transplantation (1)
- Hard Scattering (1)
- Health policy (1)
- Heart (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatotoxicity (1)
- Herbaria (1)
- High-dose chemotherapy (1)
- Histology (1)
- Homeostasis (1)
- Hsp70 (1)
- Human genetics (1)
- Hypertension (1)
- Hypoxic responses (1)
- IHC (1)
- IWRM (1)
- Icelandic Family Sagas (1)
- IgG substitution therapy (1)
- Immunogenetics (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Infection (1)
- Intensity interferometry (1)
- Intensive care unit (1)
- International Law (1)
- Internationales Recht (1)
- Interventional oncological treatment (1)
- Intravenous injections (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ions (1)
- Jet Physics (1)
- Jet Substructure (1)
- KDIGO (1)
- KIR (1)
- Konstitutionalismus (1)
- Kupffer cells (1)
- LCH (1)
- Landesinitiative (1)
- Landesinitiative für Forschungsdatenmanagement (1)
- Langerhans cell histiocytosis (1)
- Laser interstitial thermal therapy (1)
- Lehre (1)
- Lenalidomide (1)
- Libellen (1)
- Library screening (1)
- Literarischer Stil (1)
- Literaturwissenschaft (1)
- Liver (1)
- Liver cancer (1)
- Liver cirrhosis (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Luciferase (1)
- Lymphoid Neoplasia (1)
- Lyrik (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MALAT1 (1)
- MRP4 (1)
- Macrophages (1)
- Marker genes (1)
- Material budget (1)
- Mechanisms of disease (1)
- Mena/VASP (1)
- Mesenchymal stem cells (1)
- Metabolic shift (1)
- Metabolism (1)
- Microbiology and Infectious Disease (1)
- Microglial cells (1)
- Microwave ablation (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mongolia (1)
- Monochamus galloprovincialis (1)
- Monte Carlo (1)
- Mortality (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-nucleated cardiomyocytes (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidrug-resistant organisms (1)
- Multiple myeloma (1)
- Multivariate analysis (1)
- Muscle atrophy (1)
- Musikästhetik (1)
- Mutation databases (1)
- Myocardial infarction (1)
- NCoR1 (1)
- NFDI (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH1 (1)
- NTM (1)
- Nachhaltigkeit (1)
- Namibia (1)
- Nationale Forschungsdateninfrastruktur (1)
- Neural network (1)
- Neurons (1)
- Neuroästhetik (1)
- Non-tuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- Nucleus accumbens (1)
- ORL (1)
- Oncogenes (1)
- Online monitoring (1)
- Ophiogomphus cecilia (1)
- Optogenetics (1)
- Organ allocation (1)
- Orphan disease (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Ovarian cancer (1)
- PD-L1 (1)
- PGE2 (1)
- PID prevalence (1)
- PKA (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parallelisation (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Periodontal disease (1)
- Periodontal therapy (1)
- Perturbative methods (1)
- Phaenops cyanea (1)
- Phantoms (imaging) (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- PillCamColon2 (1)
- Plasminogen (1)
- Platelets (1)
- Polyps (1)
- Portal veins (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostaglandin (1)
- Proton–proton (1)
- Pulsed SILAC (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RDM (1)
- RNA (1)
- RNA, long noncoding (1)
- RNA-binding proteins (1)
- Radiative capture (1)
- Random forest (1)
- Rapidity Range (1)
- Regression analysis (1)
- Rehabilitation (1)
- Rejection (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Article (1)
- Research Data Management (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Riftia pachyptila (1)
- S. cerevisiae (1)
- SARS CoV 2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SENP (1)
- SKI II (1)
- STED superresolution (1)
- SUMO (1)
- SVR (1)
- Safety (1)
- Sarcopenia (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Second-line treatment (1)
- Semantics (1)
- Sepsis-bundle (1)
- Sequence (1)
- Shake flask (1)
- Single muons (1)
- Single-cell RNA-sequencing (1)
- Small molecules (1)
- Specialist training (1)
- Spectrin (1)
- Sphingolipids (1)
- Stem cells (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TACE (1)
- TAVR (1)
- TGF-beta (1)
- TOR signalling (1)
- TP53 mutation status (1)
- TR (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Thrombosis (1)
- Thromboxane (1)
- Time Projection Chamber (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transarterial chemoembolization (1)
- Transcriptome analysis (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Trousseau’s syndrome (1)
- Type 2 diabetes (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- UAV (1)
- Ubiquitination (1)
- University hospitals (1)
- Universitätskliniken (1)
- VRE (1)
- Vector Boson Production (1)
- Veins (1)
- Vesicles (1)
- Viral load (1)
- Weiterbildung (1)
- Wettbewerbsrecht (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Yellow fluorescent protein (1)
- a-induced reactions (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activation (1)
- acute coronary syndrome (1)
- acute leukemia (1)
- acute lymphoblastic leukemia (1)
- adenocarcinoma (1)
- adenosine receptors (1)
- aesthetic reward (1)
- age (1)
- agriculture (1)
- alcoholic hepatitis (1)
- allogeneic stem cell transplantation (1)
- amino acids (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-EGFR therapy (1)
- antibiotic therapy (1)
- antibodies (1)
- antiepileptic drugs (1)
- antifungal combination therapy (1)
- antifungal therapy (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- architecture (1)
- ascites (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- atrophy (1)
- autophagy (1)
- b-cell lymphomas (1)
- bacteremia (1)
- bendamustine (1)
- blood (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- cAMP (1)
- cART (1)
- cancer surveillance (1)
- carbapenem resistance (1)
- cardiac I/R injury (1)
- cardiac remodeling (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell-free protein synthesis (1)
- centrosome (1)
- centrosome linker (1)
- ceramides (1)
- chemoembolization (1)
- chemorefractory metastatic colorectal cancer (1)
- chemotherapy regimen (1)
- children and adolescents (1)
- chills (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- cholestasis (1)
- chromosomal translocations (1)
- chronic kidney disease (1)
- chronic viral hepatitis (1)
- cirrhosis (1)
- co-infection (1)
- cohort study (1)
- computed tomography (1)
- confidence interval (1)
- confirmatory factor analysis (1)
- constitutionalisation (1)
- constitutionalism (1)
- coronary disease (1)
- critical care unit (1)
- critical ill patients (1)
- cutaneous T cell lymphoma (1)
- cystic fibrosis (1)
- dE/dx (1)
- damage detection (1)
- decision aids (1)
- demand-responsive approach (1)
- desmoplastic small round cell tumor (1)
- detector (1)
- dihydroceramide (1)
- dihydroceramides (1)
- direct-acting antivirals (1)
- disease progression (1)
- drone (1)
- eNPP2 (1)
- enrichment (1)
- entity and event extraction (1)
- epigenomics (1)
- experimental results (1)
- extraskeletal (1)
- familial infantile epilepsy (1)
- fatigue testing (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fine spatial resolution remote sensing (1)
- first-time shoulder dislocation (1)
- fixed-links modeling (1)
- fluid intelligence (1)
- fumonisin B1 (1)
- gap junction protein alpha 4-genotype (1)
- genetic generalized epilepsy (1)
- germ cell tumors (1)
- glass fiber reinforced materials (1)
- glioblastoma (1)
- global change (1)
- graft rejection (1)
- head-and-neck cancer (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic cell transplantation (1)
- hemiplegic migraine (1)
- hepatic fibrosis (1)
- hepatic tumor (1)
- hepatitis C (1)
- hepatitis C virus (1)
- hepatitis c (1)
- herbarium (1)
- high-dose chemotherapy (1)
- histology (1)
- homoarginine (1)
- host-microbe interaction (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- idiopathic pulmonary fibrosis (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint inhibitor (ICI) (1)
- immunohistochemistry (1)
- immunoprecipitation (1)
- immunotherapy (1)
- infection (1)
- infection control (1)
- infections (1)
- inflammatory markers (1)
- insulin resistance (1)
- interferon regulatory factor 9 (IRF9) (1)
- international legal theory (1)
- intraperitoneal therapy (1)
- intrinsically disordered region (1)
- ischemic type biliary lesions (1)
- knockout mouse (1)
- lamotrigine (1)
- land use (1)
- leukapheresis (1)
- leukemia (1)
- levetiracetam (1)
- lipoxin A4 (1)
- liver (1)
- liver abscess (1)
- liver cirrhosis (1)
- liver transplantation (1)
- long non-coding RNA (1)
- lung disease phenotype (1)
- lung function (1)
- lymphoma (1)
- l‐arginine:glycine amidinotransferase (1)
- maintenance therapy (1)
- malignancy (1)
- mass spectrometry (1)
- metastasis (1)
- methyltransferases (1)
- molecular characteristics (1)
- multi-resources mix (1)
- multidrug resistance (1)
- naturalization (1)
- neovascularization, physiologic (1)
- neuroaesthetics (1)
- neutralizing antibodies (1)
- neutropenia (1)
- nomadic lifestyles (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- non-neutropenic episode (1)
- nonstructural proteins (1)
- odds ratio (1)
- oral narratives (1)
- orthopic liver transplantation (1)
- outcome (1)
- ovary (1)
- p97 (1)
- parliament libraries (1)
- pediatric solid tumors (1)
- performativity (1)
- peritoneal carcinomatosis (1)
- pharmacoresistance (1)
- phenotype/genotype relation (1)
- phenotypic spectrum (1)
- piloerection (1)
- plant diversity (1)
- plant height (1)
- pneumonia (1)
- poetic language (1)
- point shear wave elastography (1)
- precision medicine (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- primary biliary cirrhosis (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- prognostic biomarker (1)
- quark gluon plasma (1)
- radar-based structural health monitoring (1)
- radio sensitivity (1)
- rain- and floodwater harvesting (1)
- rangeland ecosystems (1)
- rats (1)
- re-exposure (1)
- rechallenge (1)
- registry for primary immunodeficiency (1)
- reintroduction (1)
- resolution of inflammation (1)
- retrospective trial (1)
- risk assessment (1)
- rituximab (1)
- rootletin (1)
- rural-urban migration (1)
- sanitation (1)
- sarcoma (1)
- screening routine (1)
- semantic content analysis (1)
- sepsis (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- short-chain ceramide (1)
- shortening of treatment (1)
- shoulder instability (1)
- shoulder stabilization (1)
- skeletal muscle (1)
- skin (1)
- social Web (1)
- solid tumor (1)
- sorafenib (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spectra (1)
- sphinganine 1-phosphate (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spike protein (1)
- steppe ecosystem (1)
- stopping rule (1)
- structural proteins (1)
- structure-from-motion photogrammetry (1)
- sulfur-oxidizing symbiont (1)
- symbiosis (1)
- tense switches (1)
- testis (1)
- text analysis (1)
- tomography (1)
- topic detection (1)
- transcatheter aortic valve replacement (1)
- transdisciplinarity (1)
- transfemoral (1)
- transient elastography (1)
- translocation partner genes (1)
- transmission (1)
- treatment (1)
- tumor microenvironment (TME) (1)
- type I interferons (IFNs) (1)
- tyrosine kinase inhibitor (TKI) (1)
- upper gastrointestinal cancer (1)
- valproic acid (1)
- variants of concern (1)
- vascular calcification (1)
- vemurafenib (1)
- versican (VCAN) (1)
- web crawler (1)
- whole-genome sequencing (1)
- wildlife mobility (1)
- wind turbine blades (1)
- working memory capacity (1)
- x-ray techniques (1)
- Ästhetik (1)
- γ-spectroscopy (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1082)
- Frankfurt Institute for Advanced Studies (FIAS) (957)
- Informatik (920)
- Medizin (158)
- Biowissenschaften (7)
- ELEMENTS (7)
- Biochemie, Chemie und Pharmazie (6)
- Sustainable Architecture for Finance in Europe (SAFE) (6)
- Wirtschaftswissenschaften (6)
- Geowissenschaften (5)
The first study of ϕ-meson production in p–Pb collisions at forward and backward rapidity, at a nucleon–nucleon centre-of-mass energy √sNN=5.02 TeV, has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions — where y stands for the rapidity in the nucleon–nucleon centre-of-mass — the integrated luminosity amounting to 5.01±0.19 nb−1 and 5.81±0.20 nb−1, respectively, for the two data samples. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward–backward ratio for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a ratio ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT=3–4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at √s=2.76 TeV, which is used to determine a reference for the p–Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4, for a 78±3 nb−1 integrated luminosity sample.
ϕ meson measurements provide insight into strangeness production, which is one of the key observables for the hot medium formed in high-energy heavy-ion collisions. ALICE measured ϕ production through its decay in muon pairs in Pb–Pb collisions at sNN−−−√=2.76 TeV in the intermediate transverse momentum range 2<pT<5 GeV/c and in the rapidity interval 2.5<y<4. The ϕ yield was measured as a function of the transverse momentum and collision centrality. The nuclear modification factor was obtained as a function of the average number of participating nucleons. Results were compared with the ones obtained via the kaon decay channel in the same pT range at midrapidity. The values of the nuclear modification factor in the two rapidity regions are in agreement within uncertainties.
Inclusive ϒ(1S) and ϒ(2S) production have been measured in Pb–Pb collisions at the centre-of-mass energy per nucleon–nucleon pair √sNN = 5.02 TeV, using the ALICE detector at the CERN LHC. The ϒ mesons are reconstructed in the centre-of-mass rapidity interval 2.5 < y < 4 and in the transversemomentum range pT < 15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive ϒ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The ϒ(1S) and ϒ(2S) RAA, integrated over the centrality range 0–90%, are 0.37± 0.02(stat) ± 0.03(syst) and 0.10 ± 0.04(stat) ± 0.02(syst), respectively, leading to a ratio Rϒ(2S) AA /Rϒ(1S) AA of 0.28±0.12(stat)±0.06(syst). The observed ϒ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
ϒ production in p–Pb interactions is studied at the centre-of-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03 < ycms < 3.53 and −4.46 < ycms < −2.96, down to zero transverse momentum. In this work, results on the ϒ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the ϒ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the ϒ(2S) nuclear modification factor is evaluated, suggesting a suppression similar to that of the ϒ(1S). A first measurement of the ϒ(3S) has also been performed. Finally, results are compared with previous ALICE measurements in p–Pb collisions at √sNN = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02TeV
(2021)
The production of ϒ mesons in Pb–Pb collisions at a centre-of-mass energy per nucleon pair √sNN = 5.02 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5 < y < 4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the ϒ(1S) meson is suppressed by a factor of about three with respect to the production in proton–proton collisions. For the first time, a significant signal for the ϒ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2–3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2021)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the Υ(1S) meson is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant signal for the Υ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.